NasdaqGS - Nasdaq Real Time Price • USD
Roivant Sciences Ltd. (ROIV)
At close: May 13 at 4:00 PM EDT
After hours: May 13 at 7:06 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 6 | 6 | 7 | 6 |
| Avg. Estimate | -0.31 | -0.46 | 4.26 | -1.36 |
| Low Estimate | -0.37 | -1.07 | -1.03 | -1.62 |
| High Estimate | -0.23 | -0.28 | 5.35 | -1.07 |
| Year Ago EPS | -0.2 | -0.38 | -1.58 | 4.26 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 8 | 7 | 10 | 10 |
| Avg. Estimate | 32.61M | 48.38M | 150.69M | 175.52M |
| Low Estimate | 27.5M | 30M | 123.3M | 134M |
| High Estimate | 40M | 142.7M | 291M | 242.19M |
| Year Ago Sales | 27.38M | 25.07M | 61.28M | 150.69M |
| Sales Growth (year/est) | 19.10% | 93.00% | 145.90% | 16.50% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -0.36 | -0.3 | -0.31 | -0.32 |
| EPS Actual | -0.2 | -0.38 | -0.4 | 6.03 |
| Difference | 0.16 | -0.08 | -0.09 | 6.35 |
| Surprise % | 44.40% | -26.70% | -29.00% | 1,984.40% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.31 | -0.46 | 4.26 | -1.36 |
| 7 Days Ago | -0.31 | -0.46 | 4.26 | -1.36 |
| 30 Days Ago | -0.3 | -0.42 | 4.45 | -1.25 |
| 60 Days Ago | -0.3 | -0.45 | 4.55 | -1.15 |
| 90 Days Ago | -0.31 | -0.42 | -1.33 | -1.12 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | 1 | 1 | 1 | 2 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | ROIV | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | -55.00% | -- | -- | 8.30% |
| Next Qtr. | -21.10% | -- | -- | 11.90% |
| Current Year | 369.60% | -- | -- | 5.60% |
| Next Year | -131.90% | -- | -- | 13.00% |
| Next 5 Years (per annum) | -- | -- | -- | 11.05% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 4/22/2024 |
| Maintains | Goldman Sachs: Buy to Buy | 4/3/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 4/3/2024 |
| Maintains | Deutsche Bank: Buy to Buy | 4/3/2024 |
| Reiterates | Truist Securities: Buy to Buy | 3/25/2024 |
| Initiated | Wolfe Research: Outperform | 2/15/2024 |
Related Tickers
BBIO BridgeBio Pharma, Inc.
28.50
-2.06%
IMVT Immunovant, Inc.
29.88
+1.67%
CYTK Cytokinetics, Incorporated
57.89
-6.78%
ABUS Arbutus Biopharma Corporation
2.8900
+0.35%
TIL Instil Bio, Inc.
11.80
+1.90%
LEGN Legend Biotech Corporation
42.97
-0.62%
RPRX Royalty Pharma plc
28.38
+1.03%
SPRO Spero Therapeutics, Inc.
1.6500
+0.61%
ASND Ascendis Pharma A/S
132.02
-1.08%
KRYS Krystal Biotech, Inc.
154.82
+0.04%